Remedy Entertainment: CONTROL the narrative

Remedy's building of franchises is central to its long-term value creation. The company continues to expand its IP through sequels, back-catalogue optimisation, and new market penetration, with Control still selling strongly years after launch and benefiting from renewed interest following the CONTROL Resonant announcement.

The next step is scaling these franchises beyond their original audiences. Management has positioned CONTROL Resonant as an action RPG targeting a broader segment of players, not just existing fans. Early indicators, including strong wishlist growth and positive community sentiment, suggest this expansion strategy is gaining traction.

This approach improves capital efficiency over time. Each new release builds on an existing audience, reducing the risk of starting from zero. The upside is compounding franchise value. The risk is that expanding into new genres or audiences dilutes what made the original IP successful.

Remedy is evolving into a multi-project studio capable of delivering games more consistently. Management has stated that the company is on track to deliver a steady cadence of roughly one game per year, supported by its current pipeline and operating model.

This is a critical shift from historically uneven release cycles. A more predictable cadence reduces revenue volatility and supports sustained growth, particularly when combined with a growing base of royalty-generating titles.

The pipeline already reflects this structure, with CONTROL Resonant in full production and additional projects progressing. Management also highlighted improvements in execution speed and internal processes, suggesting the organisation is adapting to this model.

The opportunity is a smoother, more scalable business. The risk is that increased complexity across multiple projects leads to delays or execution issues.

Remedy’s most important shift is moving from a development-fee model to a self-publishing model. Historically, the company earned relatively predictable but capped royalty income by developing games funded and published by partners. While this reduced risk, it also limited upside, as the majority of game revenues flowed to publishers.

By self-publishing its own IP, Remedy now captures a significantly larger share of game sales and post-launch monetisation, including expansions, downloadable content, and platform deals. This creates a fundamentally different economic model, one where successful games can generate significant revenue for many years. However, this also introduces higher upfront investment and execution risk, as Remedy must now fund development and marketing itself.

The key attraction for investors is that, if executed well, this transition turns Remedy into a business with higher margins, recurring revenues, and greater control over its commercial destiny. The shift from “service provider” to “IP owner” is where most of the long-term value creation lies.

• Royalty momentum: Continued sales of Alan Wake 2 and Control support revenue growth and validate franchise strength. This helps offset development-heavy periods and improves the overall revenue mix.
  
  

• CONTROL Resonant launch: Set for September 24, over 1.5 million wishlists and top-three PlayStation pre-order rankings in the US, Germany and Brazil point to strong day-one demand and a near-term profitability inflection.

• Publishing capability build-out: Continued investment in internal publishing strengthens control over distribution and monetisation. This should increase revenue share and improve long-term margins across future titles.
  
  

• Third project reaching full production: An undisclosed new title has advanced to production readiness, widening Remedy's pipeline beyond CONTROL and Alan Wake ahead of eventual release.

• Franchise compounding: Expansion of the Remedy Connected Universe enables sequels, cross-IP storytelling, and deeper engagement. This increases lifetime value per player and strengthens the overall IP portfolio.

• Margin expansion: As revenue shifts toward royalties and back-catalogue sales, the business becomes structurally more profitable. Management targets ~30% EBITDA margins by 2027, reflecting this transformation.

Despite strategic improvements, the gaming industry remains fundamentally hit-driven. A small number of successful titles typically generate the majority of industry profits, while even well-reviewed games can underperform commercially due to competition, poor timing, or changing player preferences.

For Remedy, this risk is amplified by a relatively concentrated portfolio, where a handful of key franchises drive most of the value. While the move toward a multi-project model and franchise expansion helps mitigate this over time, the business is still heavily reliant on the success of individual releases. Investors need to be comfortable with this inherent volatility, particularly during periods with fewer launches or heavy development investment.

AAA game development is becoming increasingly expensive, time-consuming, and complex. Larger teams, higher production values, and rising player expectations all contribute to longer development cycles and higher costs. This increases the risk of delays, budget overruns, and execution challenges.

For Remedy, delays can have a meaningful financial impact by pushing revenue recognition further into the future while costs continue to be incurred. Additionally, cost inflation reduces margin potential unless offset by strong commercial performance. The impairment related to FBC: Firebreak highlights how quickly development investments can lose value if commercial expectations are not met.

The shift to self-publishing materially increases both the upside and downside of each game release. Remedy is now responsible for funding development, marketing, and distribution, meaning significant capital is committed well before any revenue is realised. This creates a higher break-even threshold for each title and increases sensitivity to launch performance.

If a major release, particularly a flagship title like CONTROL Resonant—fails to meet expectations, the financial impact could be substantial, including potential write-downs similar to those already experienced. This makes execution across not just development, but also marketing timing, platform strategy, and pricing, absolutely critical. Investors will be closely watching early performance indicators such as player engagement, reviews, and initial sales traction.